# Bristol Myers Squibb (BMY) financials

Bristol Myers Squibb reported revenue of $48.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), down 0.2% from fiscal 2024. Net income was $7.05 billion and diluted earnings per share $3.46.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $13.1 billion, up 6.9% from a year earlier.

Source: Bristol Myers Squibb's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/BMY. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Bristol Myers Squibb reported revenue of $13.1 billion, up 6.9% from a year earlier, net income of $2.16 billion and diluted earnings per share of $1.05 against $1.08 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 29 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $13.07B | $12.22B | +6.9% |
| Gross profit | $8.92B | $8.79B | +1.5% |
| Gross margin | 68.3% | 71.9% | −3.6 pts |
| Operating income | $2.84B | $3.01B | −5.4% |
| Operating margin | 21.8% | 24.6% | −2.8 pts |
| Net income | $2.16B | $2.20B | −1.8% |
| Diluted EPS | $1.05 | $1.08 | −2.8% |
| Operating cash flow | $4.18B | $6.31B | −33.8% |
| Capital expenditure | $344.0M | $320.0M | +7.5% |
| Free cash flow | $3.84B | $5.99B | −36.0% |

Page: https://aapwire.com/stocks/BMY/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
| Revenue growth | +17.3% | +6.9% | +8.6% | +15.9% | +62.6% | +9.1% | −0.5% | −2.5% | +7.3% | −0.2% |
| Gross profit | $14.48B | $14.68B | $16.09B | $18.07B | $30.75B | $36.45B | $36.02B | $34.31B | $34.33B | $34.26B |
| Operating income | $6.08B | $5.33B | $5.11B | $5.91B | −$9.19B | $7.38B | $8.29B | $7.28B | −$7.49B | $10.00B |
| Net income | $4.46B | $1.01B | $4.92B | $3.44B | −$9.02B | $6.99B | $6.33B | $8.03B | −$8.95B | $7.05B |
| Diluted EPS | $2.65 | $0.61 | $3.01 | $2.01 | −$3.99 | $3.12 | $2.95 | $3.86 | −$4.41 | $3.46 |
| Operating cash flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B |
| Capital expenditure | $1.22B | $1.05B | $951.0M | $836.0M | $753.0M | $973.0M | $1.12B | $1.21B | $1.25B | $1.31B |
| Free cash flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B |
| Gross margin | 74.5% | 70.7% | 71.3% | 69.1% | 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Operating margin | 31.3% | 25.6% | 22.7% | 22.6% | −21.6% | 15.9% | 18.0% | 16.2% | −15.5% | 20.8% |
| Net margin | 22.9% | 4.8% | 21.8% | 13.2% | −21.2% | 15.1% | 13.7% | 17.8% | −18.5% | 14.6% |
| Cash and equivalents | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Total debt | $6.57B | $7.96B | $8.60B | $50.30B | $53.67B | $50.36B | $44.61B | $44.34B | $53.03B | $49.12B |
| Shareholders' equity | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
| Diluted shares | 1.7B | 1.7B | 1.6B | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 2.0B | 2.0B |
| Dividends per share | $1.53 | $1.57 | $1.61 | $1.68 | $1.84 | $2.01 | $2.19 | $2.31 | $2.42 | $2.49 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B | $12.97B | $13.07B |
| Revenue, year on year | +7.5% | −5.6% | +0.6% | +2.8% | +1.3% | +2.6% | +5.7% | +6.9% |
| Gross margin | 61.0% | 72.9% | 72.5% | 71.9% | 67.2% | 70.2% | 71.3% | 68.3% |
| Operating income | $480.0M | $3.31B | $2.27B | $3.01B | $1.42B | $3.27B | $4.03B | $2.84B |
| Net income | $72.00M | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B | $2.16B |
| Diluted EPS | $0.04 | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 | $1.05 |
| Free cash flow | $4.06B | $1.69B | $3.56B | $5.99B | $1.60B | $757.0M | $3.09B | $3.84B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [International revenues](https://aapwire.com/stocks/BMY/kpi/international-revenues) | $4.0B | quarter to 30 Sep 2026 | up 2.6% |
| [Gross product sales](https://aapwire.com/stocks/BMY/kpi/gross-product-sales) | $18.0B | quarter to 30 Sep 2026 | down 20.1% |
| [Net product sales](https://aapwire.com/stocks/BMY/kpi/net-product-sales) | $12.6B | quarter to 30 Sep 2026 | up 6.4% |
| [Growth Portfolio revenue](https://aapwire.com/stocks/BMY/kpi/growth-portfolio-revenue) | $7.7B | quarter to 30 Sep 2026 | up 11.7% |
| [Legacy Portfolio revenue](https://aapwire.com/stocks/BMY/kpi/legacy-portfolio-revenue) | $5.4B | quarter to 30 Sep 2026 | up 0.9% |
| [Eliquis revenue](https://aapwire.com/stocks/BMY/kpi/eliquis-revenue) | $4.7B | quarter to 30 Sep 2026 | up 25.2% |
| [Opdivo revenue](https://aapwire.com/stocks/BMY/kpi/opdivo-revenue) | $2.4B | quarter to 30 Sep 2026 | down 6.2% |
| [Orencia revenue](https://aapwire.com/stocks/BMY/kpi/orencia-revenue) | $983.0M | quarter to 30 Sep 2026 | up 2.0% |
| [Yervoy revenue](https://aapwire.com/stocks/BMY/kpi/yervoy-revenue) | $793.0M | quarter to 30 Sep 2026 | up 7.3% |
| [Reblozyl revenue](https://aapwire.com/stocks/BMY/kpi/reblozyl-revenue) | $750.0M | quarter to 30 Sep 2026 | up 22.0% |
| [Breyanzi revenue](https://aapwire.com/stocks/BMY/kpi/breyanzi-revenue) | $526.0M | quarter to 30 Sep 2026 | up 46.5% |
| [Alliance and other revenues](https://aapwire.com/stocks/BMY/kpi/alliance-and-other-revenues) | $463.0M | quarter to 30 Sep 2026 | up 24.5% |
| [Camzyos revenue](https://aapwire.com/stocks/BMY/kpi/camzyos-revenue) | $420.0M | quarter to 30 Sep 2026 | up 41.9% |
| [Opdualag revenue](https://aapwire.com/stocks/BMY/kpi/opdualag-revenue) | $367.0M | quarter to 30 Sep 2026 | up 22.7% |
| [Opdivo Qvantig revenue](https://aapwire.com/stocks/BMY/kpi/opdivo-qvantig-revenue) | $334.0M | quarter to 30 Sep 2026 | up 398.5% |
| [Revlimid revenue](https://aapwire.com/stocks/BMY/kpi/revlimid-revenue) | $303.0M | quarter to 30 Sep 2026 | down 47.3% |
| [Zeposia revenue](https://aapwire.com/stocks/BMY/kpi/zeposia-revenue) | $168.0M | quarter to 30 Sep 2026 | up 4.3% |
| [Pomalyst/Imnovid revenue](https://aapwire.com/stocks/BMY/kpi/pomalyst-imnovid-revenue) | $130.0M | quarter to 30 Sep 2026 | down 80.7% |
| [Abecma revenue](https://aapwire.com/stocks/BMY/kpi/abecma-revenue) | $101.0M | quarter to 31 Dec 2025 | down 3.8% |
| [Sotyktu revenue](https://aapwire.com/stocks/BMY/kpi/sotyktu-revenue) | $100.0M | quarter to 30 Sep 2026 | up 25.0% |
| [Alliance revenues](https://aapwire.com/stocks/BMY/kpi/alliance-revenues) | $95.0M | quarter to 30 Sep 2026 | down 24.0% |
| [Sprycel revenue](https://aapwire.com/stocks/BMY/kpi/sprycel-revenue) | $73.0M | quarter to 30 Sep 2026 | down 38.7% |
| [Abraxane revenue](https://aapwire.com/stocks/BMY/kpi/abraxane-revenue) | $65.0M | quarter to 30 Sep 2026 | down 12.2% |
| [Krazati revenue](https://aapwire.com/stocks/BMY/kpi/krazati-revenue) | $58.0M | quarter to 30 Sep 2026 | up 9.4% |
| [Cobenfy revenue](https://aapwire.com/stocks/BMY/kpi/cobenfy-revenue) | $57.0M | quarter to 30 Sep 2026 | up 32.6% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
